Is Fresenius SE profitable in 2026?

Yes. FY2025 Group revenue reached €22.6bn (up 7% organically) with EBIT of €2,595 million as of December 31, 2025. FY2026 guidance targets 4-7% organic revenue growth and 5-10% core EPS growth, with an EBIT margin around 11.5%, confirmed February 19, 2026.

Does Fresenius SE still own Fresenius Medical Care?

Partially. Fresenius SE deconsolidated Fresenius Medical Care from its financial statements on November 30, 2023, but retains roughly 28.6% ownership as a financial stake, having sold about 7.2% of shares in March 2025 while pledging to keep at least 25% plus one share.

Could AI replace Fresenius Helios hospitals or Fresenius Kabi manufacturing?

No. Helios treats about 27 million patients yearly under German/Spanish hospital licensure and Kabi's biosimilars required years of clinical trials and regulatory approval. As of May 6, 2026, Fresenius is using AI via an SAP/Avelios investment for hospital administration, not to replace regulated clinical care.

Who is Fresenius's biggest competitor?

In dialysis, DaVita is the closest rival; DaVita and Fresenius Kidney Care together held roughly 71.7% of U.S. dialysis treatments as of March 26, 2026. In biosimilars, Fresenius Kabi acts as the aggressor against originator Amgen, launching denosumab biosimilars in the EU in December 2025.

What litigation risks does Fresenius face in 2026?

Fresenius Medical Care Ventures is a plaintiff in the Multiplan Health Insurance Provider MDL (MDL 3121) filed against Aetna and others in November 2025, and a 2026 investigation is examining lawsuits tied to a 2024 Class I recall of 2008 Series hemodialysis machines over PCBA leaching.

Is Fresenius SE stock a buy or being downgraded?

Mixed signals: S&P revised Fresenius SE's outlook from stable to positive by July 15, 2026, and the company issued a €1 billion dual-tranche bond on July 8, 2026, yet Morgan Stanley lowered its price target to €48 from €56 around the same period, per stockanalysis.com.

Biotech tools companies · Germany

Fresenius SE & Co. KGaA

fresenius.com ↗

German conglomerate running Helios hospitals, Kabi biosimilars/nutrition, and a big stake in dialysis firm FME.

Hard to displace

Assessed 24 July 2026 · Evidence as of 24 July 2026

Strong structural protection; the business model survives ai pressure.

On the recordSince 24 July 2026 · Checkable from November 2026 · Every call on the record Checkpoint: Q3/2026 results confirming whether the twice-raised FY2026 guidance holds

The call

A century-old healthcare group with regulated, physical businesses that AI has not yet touched, facing its real pressure from biosimilar price wars and dialysis-arm litigation instead.

Fresenius runs hospitals across Europe, makes injectable drugs and copies of expensive biologics, and supplies medical equipment to patients worldwide. It is hard to replace because governments require years of permits before new hospitals can open or new drugs can sell, and Fresenius owns the physical buildings and factories that serve millions of patients every year. The biggest risk is the lawsuits and recalls tied to its old dialysis business, which it partly spun off in 2023 but still partially owns, and whether it can sell off more of that stake without stumbling.

Why

AI pressure: None apparent. AI shows up as a tool Fresenius buys (its Avelios hospital-software investment), not as a rival taking hospital or drug-manufacturing share yet. Could AI do the core job? Unlikely.

Bigger players: Sandoz and Celltrion biosimilars. Sandoz and Celltrion already sell competing biosimilars, pressuring pricing on Kabi launches like Stimufend, Otulfi, Idacio and Conexxence. Could a giant copy it? No, they are blocked.

What protects it. FDA/EMA approval barriers, sterile-injectable manufacturing scale, and Helios's licensed hospital network across Germany and Spain are hard to replicate fast.

What would change this call

Fresenius Kabi biosimilar revenue growth rate reported for FY2026 vs 2025's ~50%. Slowing growth would show Sandoz/Celltrion price competition eroding Kabi's biosimilar gains.
Q2/2026 earnings confirm or miss twice-raised FY2025 guidance trajectory. A miss would show margin pressure from biosimilar pricing or Helios costs materializing.
Further reduction of Fresenius's FME stake below current level through 2026. Faster-than-planned stake sales could signal balance-sheet strain from FME litigation costs.

Key numbers

FY2025 revenue €22.6bn, up 7% organic (2025-12-31)
Kabi biosimilars grew about 50% in 2025 (2025-12-31)
Helios treats about 27 million patients a year (2026-05-06)

Named risks

FME litigation including Class I hemodialysis machine recall and MDL 3121 filed Nov 2025. Severity: high
Pace of further FME stake sales could affect Fresenius SE equity-income line. Severity: medium
Biosimilar price compression accelerating beyond FY2026 guidance. Severity: medium
US tariff exposure on remaining ~10% of group revenue not currently sheltered. Severity: low
Helios leadership transition on July 1, 2026 could disrupt hospital-segment execution. Severity: low

Rivals, as read in July 2026

Rival	Direction	Evidence
DaVita	contesting	DaVita and Fresenius Kidney Care hold ~71.7% combined US dialysis share as of 2026-03-26
Amgen	gaining on	Fresenius Kabi launched denosumab biosimilars in EU Dec 2025 after 2025 patent settlement with Amgen
Baxter International	contesting	Competes in dialysis devices and IV/infusion products across shared markets
B. Braun Melsungen	contesting	Rival German maker of infusion, nutrition, and dialysis-adjacent products
Asklepios/Sana	contesting	Regional German private hospital operators competing with Fresenius Helios

Questions people ask

Is Fresenius SE profitable in 2026?: Yes. FY2025 Group revenue reached €22.6bn (up 7% organically) with EBIT of €2,595 million as of December 31, 2025. FY2026 guidance targets 4-7% organic revenue growth and 5-10% core EPS growth, with an EBIT margin around 11.5%, confirmed February 19, 2026.
Does Fresenius SE still own Fresenius Medical Care?: Partially. Fresenius SE deconsolidated Fresenius Medical Care from its financial statements on November 30, 2023, but retains roughly 28.6% ownership as a financial stake, having sold about 7.2% of shares in March 2025 while pledging to keep at least 25% plus one share.
Could AI replace Fresenius Helios hospitals or Fresenius Kabi manufacturing?: No. Helios treats about 27 million patients yearly under German/Spanish hospital licensure and Kabi's biosimilars required years of clinical trials and regulatory approval. As of May 6, 2026, Fresenius is using AI via an SAP/Avelios investment for hospital administration, not to replace regulated clinical care.
Who is Fresenius's biggest competitor?: In dialysis, DaVita is the closest rival; DaVita and Fresenius Kidney Care together held roughly 71.7% of U.S. dialysis treatments as of March 26, 2026. In biosimilars, Fresenius Kabi acts as the aggressor against originator Amgen, launching denosumab biosimilars in the EU in December 2025.
What litigation risks does Fresenius face in 2026?: Fresenius Medical Care Ventures is a plaintiff in the Multiplan Health Insurance Provider MDL (MDL 3121) filed against Aetna and others in November 2025, and a 2026 investigation is examining lawsuits tied to a 2024 Class I recall of 2008 Series hemodialysis machines over PCBA leaching.
Is Fresenius SE stock a buy or being downgraded?: Mixed signals: S&P revised Fresenius SE's outlook from stable to positive by July 15, 2026, and the company issued a €1 billion dual-tranche bond on July 8, 2026, yet Morgan Stanley lowered its price target to €48 from €56 around the same period, per stockanalysis.com.

Timeline

2026-07-15S&P revises Fresenius SE outlook from stable to positive
2026-07-08Fresenius settles €1 billion dual-tranche bond issuance
2026-07-02Fresenius Kabi launches citrate-free biosimilar Idacio in the US
2026-07-01Christian Pawlu becomes Fresenius Helios CEO, succeeding Robert Moller
2026-05-06Fresenius and SAP invest in Avelios Medical for AI-native hospital IT
2026-02-25FY2025 results: revenue €22.6bn, EBIT €2,595 million
2026-02-19FY2026 guidance issued: 4-7% organic revenue growth, ~11.5% EBIT margin
2025-12-01Denosumab biosimilars Conexxence/Bomyntra launch in Europe
2025-11-01Fresenius Medical Care Ventures joins Multiplan MDL 3121 litigation
2025-03-17Fresenius sells about 7.2% of Fresenius Medical Care shares
2023-11-30Fresenius Medical Care deconsolidation completed

Revision history

24 July 2026

First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.

In the same band

Merck KGaA (MilliporeSigma)Intertek Group plc Eurofins Scientific SE